<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62186">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053636</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-80881-001</org_study_id>
    <secondary_id>2013-000288-10</secondary_id>
    <secondary_id>BIG 2-13</secondary_id>
    <nct_id>NCT02053636</nct_id>
  </id_info>
  <brief_title>A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer</brief_title>
  <acronym>FINESSE</acronym>
  <official_title>An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the objective response rate (ORR) of single agent
      lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified
      with 11q amplification, or FGFR1-non amplified without 11q amplification.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Every 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor evaluation every 8 weeks throughout the study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>lucitanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hard gelatine capsules of 5 and 10 mg, 15 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lucitanib</intervention_name>
    <arm_group_label>lucitanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast adenocarcinoma.

          -  Presence of an accessible metastatic lesion for biopsy or at least one archived
             metastatic tumour sample.

          -  Prior first-line hormonal therapy in the metastatic setting.

          -  Demonstrated progression of disease by radiological or clinical assessment.

          -  Female patient, aged ≥18 years old.

          -  Estimated life expectancy &gt;3 months.

          -  Normal Left ventricular function

          -  Adequate haematological, hepatic and renal functions.

          -  For women with childbearing potential, a negative pregnancy test prior to initiation
             of the study drug and willingness to use an effective contraception.

          -  Ability to swallow oral capsules.

        Exclusion Criteria:

          -  More than two lines of chemotherapy and two lines of hormonal therapy with or without
             targeted therapy in the metastatic setting.

          -  Previous treatment with bevacizumab within 3 months of first dose of Investigational
             Medicinal Product.

          -  Active central nervous system metastases, cerebral oedema, and/or progressive growth.

          -  Patients with impaired cardiac function.

          -  Patients with history of thrombotic disorders or hereditary risk factors of
             thromboembolic events

          -  Serum potassium level below Lower Limit of Normal

          -  Uncontrolled hypothyroidism.

          -  Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice André, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Cortes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Vall d'Hebrón, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IRIS</last_name>
    <email>clinicaltrials@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
